Literature DB >> 15629263

Effects of salmeterol on cilia and mucus in COPD and pneumonia patients.

G Piatti1, U Ambrosetti, P Santus, L Allegra.   

Abstract

The present study was performed to evaluate the effects of salmeterol xynaphoate on ciliary beat frequency (CBF) of nasal epithelium and on rheological parameters of tracheobronchial mucus. We studied 10 steady-state COPD patients, eight patients with community-acquired pneumonia and eight healthy subjects as controls. They underwent a nasal brushing of the inferior turbinate to study the CBF in basal conditions and following application of salmeterol at 10(-5), 10(-6), 10(-7) and 10(-8) M concentrations directly to the epithelial samples. We also collected sputum samples, in COPD patients only, by the technique for "protected expectoration" for the rheological assessment in basal conditions and following addition of salmeterol at 10(-5), 10(-6), 10(-7) and 10(-8) M concentrations. Only samples with basal viscosity values higher than 2000 mPa/s were admitted. Our results confirmed previous studies that demonstrate a ciliostimulating effect induced by salmeterol. The mean basal CBF was 11.18 +/- 0.75 Hz in control subjects, while the pathological subjects showed a markedly lower basal values: 8.64 +/- 0.88 Hz (p = 0.000) and 8.83 +/- 0.68 Hz (p = 0.000), in COPD and pneumonia patients, respectively. Salmeterol induced ciliostimulation in both patients groups as well as the healthy controls. The maximum increase in CBF, highly significant, was obtained at 10(-6) M concentrations of salmeterol, while this effect decreased at lower concentrations. Regarding the action of salmeterol on rheological parameters, a direct effect of salmeterol on mucus cannot been demonstrated and the described beneficial clinical effects on mucociliary clearance occurring in vivo are probably related to an indirect effect of stimulation of ciliary beat. This preliminary study suggests that, in addition to COPD, salmeterol could be a useful therapeutic agent in pneumonia also, for its positive effect on ciliary movement other than bronchodilation, but this finding needs further investigations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15629263     DOI: 10.1016/j.phrs.2004.07.006

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  15 in total

1.  Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro.

Authors:  J Milara; M Armengot; P Bañuls; H Tenor; Rolf Beume; E Artigues; J Cortijo
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

2.  Sex hormone-dependent regulation of cilia beat frequency in airway epithelium.

Authors:  Raksha Jain; Jennifer M Ray; Jie-hong Pan; Steven L Brody
Journal:  Am J Respir Cell Mol Biol       Date:  2011-10-27       Impact factor: 6.914

Review 3.  Seeing cilia: imaging modalities for ciliary motion and clinical connections.

Authors:  Jacelyn E Peabody; Ren-Jay Shei; Brent M Bermingham; Scott E Phillips; Brett Turner; Steven M Rowe; George M Solomon
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-03-01       Impact factor: 5.464

Review 4.  Routine Use of Budesonide/Formoterol Fixed Dose Combination in Elderly Asthmatic Patients: Practical Considerations.

Authors:  Nicola Scichilone; Fulvio Braido; Federico Lavorini; Mark L Levy; Omar S Usmani
Journal:  Drugs Aging       Date:  2017-05       Impact factor: 3.923

Review 5.  Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease.

Authors:  Gillian M Keating; Paul L McCormack
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  The beta agonist lung injury trial prevention. A randomized controlled trial.

Authors:  Gavin D Perkins; Simon Gates; Daniel Park; Fang Gao; Chris Knox; Ben Holloway; Daniel F McAuley; James Ryan; Joseph Marzouk; Matthew W Cooke; Sarah E Lamb; David R Thickett
Journal:  Am J Respir Crit Care Med       Date:  2014-03-15       Impact factor: 21.405

7.  Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium.

Authors:  Mineo Katsumata; Tomoyuki Fujisawa; Yosuke Kamiya; Yuko Tanaka; Chiaki Kamiya; Yusuke Inoue; Hironao Hozumi; Masato Karayama; Yuzo Suzuki; Kazuki Furuhashi; Noriyuki Enomoto; Yutaro Nakamura; Naoki Inui; Masato Maekawa; Mitsutoshi Setou; Hiroshi Watanabe; Koji Ikegami; Takafumi Suda
Journal:  BMC Pulm Med       Date:  2022-05-08       Impact factor: 3.320

8.  Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke.

Authors:  Ruth E MacRedmond; Catherine M Greene; Delbert R Dorscheid; Noel G McElvaney; Shane J O'Neill
Journal:  Respir Res       Date:  2007-11-22

9.  The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.

Authors:  Chris Dalby; Tomasz Polanowski; Thomas Larsson; Lars Borgström; Staffan Edsbäcker; Tim W Harrison
Journal:  Respir Res       Date:  2009-10-31

10.  Pulmonary Rehabilitation in COPD: A Reappraisal (2008-2012).

Authors:  Pierachille Santus; Linda Bassi; Dejan Radovanovic; Andrea Airoldi; Rita Raccanelli; Francesco Triscari; Francesca Giovannelli; Antonio Spanevello
Journal:  Pulm Med       Date:  2013-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.